Fatty acid microsomal -oxidation involves cytochrome P450 enzymes. Some of them belonging to the CYP4F3 family are mainly expressed in the liver, making this organ a major player in energy homeostasis and lipid metabolism. To study this important regulation pathway, we used HepaRG cells, which gradually undergo a complete differentiation process. Even at the early stage of the differentiation process, CYP4F3B generated by alternative splicing of the CYP4F3 gene represented the prevalent isoform in HepaRG cells as in the liver. Its increasing expression associated with hepatocyte differentiation status suggested a hepatic-specific control of this isoform. As in liver microsomes, the catalytic hydroxylation of the CYP4F3B substrate [1- 
Introduction
Interest in lipid metabolism has greatly increased in the last decade because of its strong influence onto obesity leading to metabolic syndrome pathologies including vascular and liver disorders. Common to obesity-related dyslipidemia and hypertriglyceridemia is the excessive storage of fatty acids (FAs) in the liver (steatosis), frequently referred as nonalcoholic fatty liver disease. However, we are just beginning to understand how FAs induce oxidative stress and progression of steatosis to steatohepatitis characterized by inflammation processes (nonalcoholic steatohepatitis). Associated alterations in glucose, FAs, and lipoprotein metabolism may account for causal or responsive effectors to occurrence of these abnormalities (Fabbrini et al., 2010) . Even if the major FA catabolism pathway is ␤-oxidation, there is a growing body of evidence that another way, the microsomal -oxidation mediated by cytochrome P450 (P450) enzymes, plays a pivotal role in synthesis of lipid mediators, energy homeostasis, and lipid accumulation (Hardwick, 2008) . This latter pathway, which mainly involves the CYP4A/4F subfamilies that preferentially hydroxylate the terminal methyl group of the FA chain (Sanders et al., 2006; Hsu et al., 2007) , provides a novel route to eliminate the potential toxic levels of free FAs. Therefore, they may represent therapeutic targets, and efforts in increasing our understanding of their regulation would be very helpful.
Among P450s, including CYP4A11, CYP4F2, and CYP4F3A/3B, the latter is the best known to -hydroxylate the essential FA arachidonate to 20-HETE, a potent vasoactive ecosanoid and anti-inflammatory agent (Kalsotra and Strobel, 2006; Fer et al., 2008) . The CYP4Fs are predominantly expressed in liver and kidney, although CYP4F3A is found in myeloid tissue. Different regulation for their tissue-dependent expression has been proposed. For instance, tissuespecific transcription factors such as the hepatocyte nuclear factor 4␣ (HNF4␣) controls the expression of key genes involved in hepatic very low-density lipoprotein metabolism (Petrescu et al., 2002) . Alternative splicing is also increasingly recognized as a shared theme in P450 gene regulation to generate tissue-specific expression of P450s (Nelson et al., 2004) . A pertinent example is provided by the functionally distinct CYP4F3 isoforms, which are regulated by alternative promoter usage and mutually exclusive exon splicing (Christmas et al., 2001) . Selection of exon 4 generates the CYP4F3A isoform, which has a low K m for leukotriene B4 and is mainly expressed in neutrophils. Meanwhile, selection of exon 3 generates an alternative isoform (CYP4F3B) that has 44-fold lower efficiency of inactivating leukotriene B4, which is expressed in liver and has a preference for arachidonic acid (AA) as a substrate to convert it to 20-HETE. These contrasting abilities of the CYP4F3 isoforms allow versatility function but require strict controls that are still poorly documented.
In addition, expression of CYP4A/4F gene families can be highly modulated by various environmental factors, for instance, fasting, high-fat diet, hypolipidemic drugs, or peroxisome proliferators (Hardwick, 2008; Hardwick et al., 2009) , and by an endogenous lipid mediator such as prostaglandin A1 (Antoun et al., 2008) . Moreover, different intracellular types of FAs and their metabolites may coordinate energy homeostasis by activation or repression of distinct transcriptional factors including peroxisome proliferators-activated receptors (PPAR␣, PPAR␤, PPAR␥), sterol regulatory element-binding proteins (SREBP-1 and SREBP-2), and liver X receptor (LXR␣), suggesting involvement of distinct signaling pathways.
Studies on regulation processes of P450s involved in these pathways have been hampered by the limited availability and the inherent variability of human liver material. In this study, the CYP4F3B expression has been analyzed in HepaRG cells and compared with two different human hepatoma-derived cell lines, namely HepG2 and Huh-7, known to support several liver-specific functions. In contrast to the others, HepaRG cells display characteristics of hepatic progenitors, i.e., high capacity for self-renewal and expression of numerous markers of early hepatic progenitors or oval cells (Cerec et al., 2007) . Moreover, those cells directed toward the hepatocyte lineage at confluence can undergo a gradual and complete hepatic differentiation program similar to normal hepatocytes with expression of a large panel of liver-specific genes, including the major drug-metabolizing enzymes (Aninat et al., 2006; Le Vee et al., 2006) . Here, we showed that HepaRG cells expressed the tissue-specific CYP4F3B isoform and the CYP4A11 at higher levels than other hepatocellular cell lines and that their expression levels were strongly linked to the cell differentiation status. Moreover, the CYP4F3B catalytic activity was similar to that observed in human liver microsomes, and exposure of differentiated HepaRG cells to various FAs induced a hepatocyte steatosis and adaptive response that participated to reduce neolipogenesis. All together, our results showed that FA metabolism in HepaRG hepatocytes is highly similar to human liver.
Materials and Methods

Chemicals. Radiolabeled [1-
14 C]Z9(10)-epoxystearic acid (Z9(10)-EpSTA; 57 Ci/mol) was from CEA/Saclay (Gif-sur-Yvette, France). Z9(10)-Epoxystearic acid, stearic acid, palmitic acid, oleic acid, linoleic acid, ␣-linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and AA were obtained from Cayman Chemical (SPI Bio, Massy, France). The silylating reagent N,O-bistrimethylsilyltrifluoroacetamide containing 1% of trimethylchlorosilane was obtained from Pierce Europe (Ound-Beijerland, The Netherlands). All chemicals and solvents were purchased from Merck (Darmstadt, Germany) and Sigma-Aldrich (Lyon, France).
Culture Conditions. The new cell line, HepaRG, established by Gripon et al. (2002) , was maintained as described previously, in the growth medium composed of William's E medium (Invitrogen, Carlsbad, CA) supplemented with L-glutamine, 10% fetal calf serum (HyClone Laboratories, Logan, UT), 5 g/ml insulin (Sigma-Aldrich), and 5.10 Ϫ5 M hydrocortisone hemisuccinate (Upjohn Pharmacia, Puurs, Belgium). Cells were seeded at the density of 2.6 ϫ 10 4 cells/cm 2 and reached confluence in 4 days. After 15 days, they were maintained in the growth medium supplemented with 2% DMSO (SigmaAldrich) for 2 more weeks. The medium was renewed every 2 or 3 days. The HepG2 cell line, a derived clone, C3A, and the Huh-7 cell line were obtained from American Type Culture Collection (Manassas, VA). They were maintained in the growth media recommended by American Type Culture Collection and used after 7 days of confluence for the Huh-7 cell line and after 3 weeks of culture for the HepG2 cell line.
To evaluate the effect of DMSO and the involvement of HNF4␣ on the CYP4F3B expression, differentiated HepaRG cells were cultured 3 days without DMSO before treatment. Then HepaRG cells were treated for either 18 h with 0.1 or 2% DMSO or 24 h with 50, 100, and 200 M linoleic acid.
For the FA treatment, differentiated HepaRG cells were incubated with different saturated fatty acids, monounsaturated fatty acids (MUFAs), or polyunsaturated fatty acids (PUFAs) at concentrations ranging from 50 to 200 M (stearic acid, palmitic acid, oleic acid, linoleic acid, ␣-linolenic acid, EPA, DHA, and AA) for 6, 15, or 24 h in a DMSO and fetal calf serum-deprived medium supplemented with 1% bovine serum albumin fraction V fatty acid free. In some experiments, a combination of palmitic/oleic acids with a ratio 1:1 was also used.
Peripheral blood mononuclear cells were isolated from healthy blood donor's buffy coats by centrifugation on Ficoll-Hypaque gradient (GE Healthcare, Chalfont St. Giles, UK). Access to biopsy material was in agreement with French laws and satisfied the requirements of the Ethics Committee of the institution.
Incubation of HepaRG Cells with Z9(10)-EpSTA. Differentiated HepaRG cells were incubated with 20 M radiolabeled [1-14 C]Z9-(10)-epoxystearic acid (specific activity, 4 Ci/mol), a discriminating substrate of CYP4F3 (Le Quéré et al., 2004) , for 30 min at 37°C. Z9-(10)-EpSTA was added in DMSO to 5 ml of culture medium. After incubation, medium and cells (2 ml of PBS) were collected and stored at Ϫ80°C.
Isolation of Total RNA, Northern Blot, and Reverse Transcription. Total cell RNA was extracted by the Total SV RNA kit (Promega, Madison, WI) or semiautomatic RNA extraction using the ABI Prism 6100 Nucleic Acid PrepStation. Concentration of each sample was spectrophotometrically determined, and their integrity was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). RNAs were fractionated on a 1.5% agarose gel and analyzed by standard Northern blot procedure. Control of the RNA amount transferred onto filters was performed after methylene blue staining. Reverse transcription (RT) mixtures using a high-capacity cDNA kit (Applied Biosystems, Foster City, CA) contained 50 l of pure RNA samples. RT reaction proceeded for 10 min at 25°C, 2 h at 37°C, and cDNAs were then stored at Ϫ80°C.
Real-Time RT-Polymerase Chain Reaction. Quantitative polymerase chain reaction (PCR) was performed by real-time fluorescent PCR using the ABI PRISM7000 sequence detection system (Applied Biosystems), and detection used a fluorescent dye (SYBR Green) according to the manufacturer's recommendations. Primer pairs of transcript were either chosen with primers 3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3www.cgi) ( Table 1) or purchased from Applied Biosystems [PEPCK1, Hs00159918_m1*; CYP4A11, Hs04194779_g1*; glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hs02758991_g1*]. Reactions were carried out with 10 to 20 ng of cDNA. Three-step thermocycling was performed for 40 cycles. To normalize the amount of total RNA present in each reaction, we amplified the housekeeping gene GAPDH. PCR amplifications were done in triplicate for each sample.
Microsomal Preparation from Tissue and Cell Culture. Human biopsies were obtained from adult donors undergoing resection for primary and secondary tumors. Microsomes from human livers and HepaRG cells were prepared after homogenization of the tissues or cells as described previously (Berthou et al., 1989) .
Western Blot. Microsomal proteins (1-5 g) were resolved on 9% SDSpolyacrylamide gel electrophoresis, transferred onto nitrocellulose membrane, and blotted overnight at 4°C with a rabbit polyclonal antibody, anti-CYP4F2 (RDI, Flanders, NJ), cross-reacting with CYP4F3A, CYP4F3B, and CYP4F12 but not with CYP4A11. Specific protein expression was compared with the spot obtained with human recombinant CYP4F3B-containing insect cell microsomes (Supersomes; BD Gentest, Woburn, MA) and human liver biopsy microsomes (enhanced chemiluminescence; GE Healthcare). Densitometry analysis was performed using BIO1D scanning software (Vilber Lourmat, Marne-la-Vallée, France).
Proteins (50 g) from HepaRG cells were resolved on 4 to 12% gradient SDS-polyacrylamide gel electrophoresis, transferred onto nitrocellulose, and blotted with either CYP4F3B-specific anti-peptide antibody raised against the amino acids encoded by the CYP4F3B-specific exon (position 232-374 from sequence AF05482 as described previously) (Antoun et al., 2008 ) (Eurogentec, Seraing, Belgium) or rabbit anti-CYP4A11 primary polyclonal antibody (ref: RDI, -CYP4A11abr; RDI). After washing with PBS, they were treated with PBS containing an anti-rabbit Ig-biotinylated species-specific secondary antibody conjugated to streptavidin-horseradish peroxidase and washed with PBS. The peroxidase activities were evidenced by enhanced chemiluminescence detection using luminol.
Immunochemical Analysis and Oil-Red O Staining. Cells were fixed with 4% paraformaldehyde for 20 min at 4°C. Incubation with a primary antibody directed against albumin (Kent Laboratories, Redmond, WA), CYP3A4 (Millipore Bioscience Research Reagents, Temecula, CA), was performed at 4°C overnight and then with the peroxidase-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 h. Peroxidase staining was obtained with 3,3Ј-diaminobenzidin/H 2 O 2 solution and counterstaining with Masson's Hemalum. Intracellular neutral lipid deposition was stained by Oil-red O. In brief, the cells were washed with ice-cold PBS twice, fixed with 4% paraformaldehyde at 4°C for 1 h, and stained with 0.2% Oil-red O in isopropanol for 10 min. The cells were then washed with 70% ethanol and water.
Lipid Extraction. Radioactivity was quantified in 100 l fractions from both medium and cell pellets. The medium and cell pellets were divided in two equal fractions, lyophilized, and either dissolved in 100 l of methanol or added to 500 l of acetate buffer, pH 5.2, containing 20 l of helixpomacia suc for selective hydrolysis of glucuronoconjugated metabolites. After overnight incubation at 37°C and extraction with ethyl acetate, compounds were dissolved in 50 l of ethanol and analyzed by RP-HPLC.
RP-HPLC and GC-MS Analyses of Metabolites.
The oxidized metabolites and residual substrates were separated by RP-HPLC using a 5-m Ultrasphere C18 column (150 ϫ 4.6 mm; Beckman Coulter, Fullerton, CA) using a mobile phase constituted of a mixture of water and acetonitrile (71:29 v/v) containing 0.2% of acetic acid at a flow rate of 2 ml/min for 35 min. The residual substrates were eluted by applying a mixture of water/acetonitrile (5:95 v/v) containing 0.2% acetic acid for 5 min. The radioactivity of RP-HPLC effluent was monitored with a computerized on-line scintillation counter (Flo-one Beta Radiometric detector; PerkinElmer Life and Analytical Sciences, Waltham, MA). The rate of radiolabeled metabolites generated was calculated from peak areas.
GC-MS analysis (electron ionization, 70 eV) was carried out on a gas chromatograph (HP 5890 Series II; Agilent Technologies) equipped with a fused silica capillary column (HP-5MS 5% phenyl methyl siloxane; 30 m ϫ 0.32 mm i.d., 0.25-m thick film) as described previously (Le Quéré et al., 2004) . Mass spectra of Me/methyl ester trimethylsilyl ether derivatives contained in peaks with retention times of 21.2 and 26.5 min showed typical fragment ions at m/z 73, 113, 155, 215, 259, and 443 (M ϩ -31) corresponding to 9,10-dihydroxyoctadecanoic acid (see Fig. 3 , peak 2) and m/z 73, 103, 155, 199, 215, 243, and 385 (M ϩ -15) corresponding to 18-hydroxy-9,10-epoxyoctadecanoic acid (see Fig. 3 , peak 5), respectively. Statistical Analyses. Data were expressed as means Ϯ S.D. Statistical analyses were performed using the nonparametric Mann-Whitney U test. Values of p Յ 0.05 were accepted as significant.
Results
Morphological and Functional Characteristics Associated with the HepaRG Cell Differentiation Program. Just after seeding, HepaRG cells appeared as a homogeneous cell population with an elongated shape characteristic of progenitor cells (Fig. 1A) . When maintained in the growth medium for 2 weeks followed by 2 additional weeks in the same medium supplemented with 2% DMSO, an active differentiation program was observed and schematically divided in four steps: step 1, elongated cells actively dividing up to reach confluence within 4 to 5 days (Fig. 1B) ; step 2, occurrence of colonies of granular cells that gradually got the appearance of hepatocyte-like cells at confluence in 1 week; and step 3, cords of cells exhibiting typical hepatocyte-like phenotype surrounded by flat sheets of clear epithelial cells after 2 weeks (Fig. 1C) . The fourth stage covering the period of DMSO exposure is associated with increased hepatocyte-like cell colonies with high polarity as evidenced by the appearance of numerous bile canaliculus-like structures (Fig. 1D,  arrowhead) .
In parallel, from step 2, hepatocyte-like colonies, but not the surrounding biliary cells, expressed sets of liver-specific functions, 
CYP4F3B AND -HYDROXYLATION OF FATTY ACIDS IN HepaRG CELLS
at ASPET Journals on June 27, 2017 dmd.aspetjournals.org Downloaded from among them plasma proteins such as transferrin and albumin (Fig. 1E , arrowhead), glycolytic enzymes such as aldolase B, and detoxication enzymes such as CYP4A11 and CYP3A4 (Fig. 1F, arrowhead) . Comparison of mRNA kinetics of these specific functions showed that the specific glycolytic enzyme expression occurred much earlier than the detoxication enzyme CYP3A4, the latter being preceded by the liverspecific transcription factor HNF4␣, which clearly occurred at day 10. Expression of all these genes gradually increased thereafter (Fig. 1G) , thus characterizing the differentiation steps of HepaRG hepatocytes. CYP4F3B Gene Expression Is Strongly Associated with the Hepatocyte Differentiation Process in HepaRG Cells. CYP4F3 gene expression was measured during the hepatic differentiation process and compared with other differentiation markers. As shown in Table 2 , the highest expression for CYP4F3 was found in differentiated hepatocytes from step 3, with a gradual increase during the differentiation process similar to CYP3A4 and HNF4␣ expression profiles. Aldolase B accumulated at an earlier stage (step 2), whereas C/EBP␣ expression remained unchanged throughout the process. From day 15, HepaRG cells were exposed to 2% DMSO resulting within 10 days in dramatic increased levels of CYP4F3 (3-to 4-fold, step 4), CYP3A4 (20-fold), and HNF4␣ (2-fold). To determine the contribution of DMSO per se added to the culture medium as an inducer of CYP4F3 expression, differentiated HepaRG cells were exposed to increasing concentrations of DMSO up to 2% for 18 h. A 5-to 6.4-fold induction with 1 and 2% DMSO, respectively, was found. Western blot analysis showed an accumulation of this enzyme in differentiated HepaRG cells (step 4) at a level close (70%) to that found in a human liver tissue (Fig. 2, A and B) . This expression level was 10-fold higher than in HepG2 cells and at least twice as high as in HepG2/C3A and Huh-7 cells (Fig. 2C) .
To investigate which CYP4F isoform was predominantly expressed in HepaRG cells, we used two sets of primers especially designed to selectively amplify CYP4F3A and CYP4F3B mRNA isoforms. Considering expression in white blood cells arbitrarily set at 1, CYP4F3B mRNA expression seemed to be, by far, the predominant isoform in the liver and fully differentiated HepaRG cells (Table 3) . Because HNF4␣ is a key regulator of liver-specific gene expression, HepaRG cells were exposed to one of its ligands, the linoleic acid, for 24 h to study the effect on CYP4F3B and CYP3A4 expression (Yuan et al., 2009) . Whereas CYP3A4 expression, one of the HNF4␣ target genes, increased, CYP4F3B expression remained unchanged (Fig. 2E) . The CYP4F3B expression profile during the differentiation process was then compared with other key genes involved in the regulation of the lipid metabolism (Table 4 ; Fig. 2D ). Both CYP4A11 and PPAR␣ exhibited a similar profile to CYP4F3B throughout the hepatocyte differentiation process, whereas both PPAR␥ and SREBP-1c expression slightly increased up to the confluence stage but were poorly related to the hepatic differentiation process (step 3).
Metabolism of Z9(10)-Epoxystearic Acid by CYP4F3B in HepaRG Cells. The catalytic functionality of CYP4F3B was assessed by incubating for 30 min differentiated HepaRG cells with [1-14 C]Z9(10)-EpSTA, a discriminating CYP4F3B substrate (Le Quéré et al., 2004) . Measurement of the residual radioactivity of the medium and the cell pellet showed a disappearance of more than 30% of the starting radioactivity, suggesting an efficient decarboxylation of the substrate probably by ␤-oxidation. Analysis of the culture medium and the cell pellet before (Fig. 3 , A and C) and after (Fig. 3, B and D) treatment with helixpomacia suc suggested the presence of glucuronoconjugates (Fig. 3 , A and C, peak 1) and showed the presence of 9,10-dihydroxystearic acid (Fig. 3, B and D, peak 2) and unidentified metabolites. On the other hand, RP-HPLC (Fig. 3) demonstrated the -hydroxylation of Z9(10)-epoxystearic acid to 18-hydroxy-9,10-epoxystearic acid (Fig. 3D, peak 5) , evidencing the involvement of CYP4F3B in the reaction. Moreover, incubation of microsomes from human liver (Fig. 3E ) and differentiated HepaRG cells (Fig. 3F) with [1-14 C]Z9(10)-EpSTA was performed. It is noteworthy that the same RP-HPLC profile of radiolabeled metabolites was observed in both extracts: 9,10-dihydroxystearic acid (peak 2), 18-hydroxy-9,10-epoxystearic acid (peak 5), and a low amount of 9,10,18-trihydroxystearic acid (peak 4) were generated. Note that this RP-HPLC profile was similar to that previously obtained after incubation of human liver microsomes with Z9(10)-EpSTA (Le Quéré et al., 2004) . The chemical structure of these metabolites was confirmed by GC-MS analysis (data not shown).
Influence of Saturated FAs, MUFAs, and PUFAs on P450s Expression in HepaRG Cells. Hepatic expression of CYP4F and CYP4A genes can be induced by a number of different compounds such as FAs. To determine whether saturated, monounsaturated, or polyunsaturated fatty acids can modulate P450 hydroxylase expression, we exposed for 6, 15, and 24 h differentiated HepaRG cells to increasing concentrations of stearic acid (C18:0), palmitic acid (C16: 0), oleic acid (C18:1, -9), and linoleic acid (C18:2, -6) and to a combination of palmitic/oleic acids that simulates dietary intake (Fig. 4) . Regardless of the fatty acid concentrations ranging from 50 A), at confluence (step 2; B), before DMSO addition (step 3; C), and after 2-week exposure to 2% DMSO (step 4; D). E and F, albumin (E) and CYP3A4 (F) immunolocalization in hepatocyte colonies at step 4. Black arrowheads indicate the staining of interest in hepatocyte cords. BC, biliary cells; H, hepatocytes. Scale bar, 100 m. G, aldolase B, CYP3A4, HNF4␣, and C/EBP␣ mRNA expression was measured by Northern blot during the different steps of differentiation.
to 200 M or the duration of treatment, no significant changes in CYP4F3B and CYP4A11 expression were detected. CYP4F2 and CYP4F12 expression was only transiently up-regulated 6 h after the FA treatment. Note that these inductions were not observed in cells treated with palmitic/oleic acid mixtures. In parallel, during the 6-to 15-h treatment period, PPAR␣ expression remained stable in all conditions before decreasing after 24 h of treatment (see Fig. 6 and data not shown), suggesting at that time a modulation of the lipid metabolism.
Influence of Different MUFAs and PUFAs on Lipid Metabolism Regulator Genes in HepaRG Cells.
To link HepaRG P450 catalytic activity to lipid metabolism, we exposed differentiated HepaRG cells to six distinct PUFAs [oleic acid (C18:1, -9); linoleic acid (C18:2, -6); ␣-linolenic acid (C18:3, -3) and its two derivatives, eicosapentaenoic acid (C20:5, -3) and docosahexaenoic acid (C22:6, -3); and arachidonic acid (C20:4, -6)] for 24 h, and steatosis was evaluated. Twenty-four hours after FA treatments, microvesicular steatosis characterized by accumulation of lipid droplets was assessed by Oil-red O staining (Fig. 5) . Steatosis occurred in hepatocyte colonies and was triggered by all the different treatments. EPA and DHA gave the greatest lipid accumulation. In parallel, expression levels of lipid metabolism regulator genes (SREBP-1c, FAS, PPAR␣, PPAR␥) were determined and compared with glucose metabolism enzymes (aldolase B and PEPCK-1) and to haptoglobin, an acute phase protein (Fig. 6) . In the presence of all PUFAs tested, lipogenic gene expression was repressed, whereas CYP4F3B and CYP4A11 (data not shown) expression remained unchanged. Haptoglobin RNA levels were poorly modulated except with DHA, which induced a dramatic inhibition of its expression. It is noteworthy that PPAR␣ expression, expected to be up-regulated, was down-regulated with a maximum inhibition also observed with DHA (up to 3-fold). Aldolase B glycolytic enzyme expression was clearly repressed by all PUFAs, whereas PEPCK-1, the neoglucogenic enzyme, expression was only drastically reduced by DHA.
Discussion
Since the liver is the main source of major P450 enzymes, it appears as the organ playing a central role in pathologies linked to obesity, such as cardiovascular and hepatic diseases, both as victim and culprit (Goetzl et al., 1995) . Indeed, by their typical common reactions to metabolize various substrates, P450 enzymes contribute to xenobiotic transformation, alcohol detoxication, and lipid oxidation. -Hydroxylation of both pro-and anti-inflammatory leukotrienes by members of the CYP4F subfamily directly contributes to the activation and resolution phases of the inflammatory response (Kikuta et al., 1994) . As demonstrated in a previous work, CYP4F3 is the major P450 isoform 
Quantification of CYP4F3 gene expression by qPCR during the different steps of the HepaRG differentiation process
Representative cell cultures of the four steps of the differentiation process were collected. Gene expression was quantified by real-time qPCR. Results are expressed as fold induction over day 2 of culture, set at 1, and represent the means Ϯ S.D. of two independent experiments performed in triplicate.
Steps of Differentiation
Days of Culture CYP4F3 Aldolase B CYP3A4 HNF4␣ C/EBP␣
Step catalyzing the -oxidation of AA and epoxyeicosatrienoic acid derivatives in the human liver (Le Quéré et al., 2004) . Until now, studies on fatty acid metabolism and its regulations by the P450s have been hampered by the absence of relevant in vitro models mimicking the human liver. Here, we demonstrated that the expression level of the CYP4F3B isoform was similar in HepaRG cells and in human liver microsomes and 10 and 3 times higher than in HepG2 and Huh-7 cells, respectively. CYP4A11 was also highly expressed in HepaRG when compared with HepG2 and Huh-7 cells. It is noteworthy that CYP4F3B and CYP4A11 expression was strictly associated with the differentiation process of HepaRG cells, which was characterized by a gradual increased expression up to hepatocyte maturation of HNF4␣, a well known master regulator of hepatic specific genes, specific enzymes of glucose metabolism such as aldolase B, and P450 enzyme families involved in phase 1 detoxication metabolism such as CYP3A4. These results strongly raise the question of its tissue-specific regulation.
Localization of CYP4F3 was thought to be restricted to myeloid cells until tissue-specific expression of one functionally distinct isoform, CYP4F3B, was discovered in the liver (Christmas et al., 2001 ). CYP4F3A and CYP4F3B were both expressed in the fetal liver, but it was suggested that CYP4F3A was associated with its transient hematopoietic function. This study supports our observation that CYP4F3A was very weakly expressed in HepaRG cells regardless of their differentiation status, thus excluding the possibility of a balanced expression between the two isoforms in hepatic cells. This also confirms this alternative splicing as a tissue-specific regulation (Christmas et al., 2001 ) and supports that its control could take place during the early stage of hepatic organogenesis.
CYP4F3B expression during hepatocyte differentiation matched that of HNF4␣, CYP3A4, and CYP4A11, suggesting that various P450s might share common mechanisms controlling gene expression mediated by liver-specific transcription factors and nuclear receptors. HNF4␣ modulates the expression of a large number of genes involved in the uptake of lipoproteins, synthesis of cholesterol and triglycerides, and very low-density lipoprotein processing (Hwang-Verslues and Sladek, 2010) . A potential binding site for HNF4␣ was identified in the CYP4F3B isoform promoter in HepG2 cells (Christmas et al., 2003) . Although CYP4F3B and CYP3A4 were expressed once HepaRG cells expressed HNF4␣, we did not observe a correlation between HNF4␣ activation and the regulation of CYP4F3B expression. However, we did observe an increase in CYP3A4 expression, one of the well known HNF4␣ target genes after linoleic acid exposure, identified as a reversible endogenous ligand for HNF4␣ (Yuan et al., 2009) .
It is now well established that DMSO potentiates hepatocyte differentiation (Isom et al., 1985; Gripon et al., 2002) . DMSO exposure was found to greatly enhance the expression of several P450 isoforms and transporters in HepaRG cells (Aninat et al., 2006) . Expression of both CYP4F3B and CYP3A4 was up-regulated by 6-and 15-fold, respectively, in HepaRG cells when treated with 2% DMSO, whereas CYP4F3A remained barely expressed. Therefore, in agreement with Dickins (2004) , our results led us to hypothesize that CYP3A4 and CYP4F3B could be regulated by a common mechanism involving one or several nuclear receptors such as retinoid X receptor, pregnane X receptor, and constitutive androstane receptor. Lambert et al., (2009) showed that phenobarbital, an activator of constitutive androstane receptor and pregnane X receptor, enhanced CYP4F3B but repressed CYP4A11. Likewise, we observed that CYP4A11 expression was down-regulated in DMSO-treated cells. This supports the well established differential regulation of the human CYP4A genes, especially CYP4A11, which was shown to be regulated by retinoic acid, bezafibrate, and dexamethasone in human (Savas et al., 2003; Antoun et al., 2006) .
One of our major observations was related to the CYP4F3B catalytic activity in HepaRG cells. CYP4F3B from human liver microsomes was described as the major P450 isoform involved in the -hydroxylation of FA epoxides with unsaturated C18 and C20 carbon chains (Le Quéré et al., 2004) . We showed that the oxidative metabolism of 9(10)-epoxystearic acid, a discriminating CYP4F3B substrate, was identical in HepaRG cells and in human liver microsomes. This confirmed that HepaRG cells preserved the ability to metabolize C18 epoxides with high efficiency via the same pathways as in the liver (Capdevila et al., 1988) . Note that CYP4F3B was also identified as the enzyme producing 20-HETE in HepaRG cells (Antoun et al., 2008) . This functional feature of HepaRG cells offers new clues to highlight the mechanisms of toxicity induced by FA derivatives described as toxic metabolites in mammals but also by epoxyeicosatrienoic acids, found to accumulate in alcoholic liver disease in rat (French et al., 1997) .
Finally, we exposed differentiated HepaRG cells to different saturated FAs, MUFAs, and/or PUFAs to compare the regulation of CYP4F3B expression to other P450s involved in the lipid hydroxylation. No major modulation of the main P450 hydroxylase expression Representative cell cultures of the four steps of differentiation were collected. Gene expression was quantified by qPCR. Results are expressed as fold induction over the first day of culture, set at 1, and represent the means Ϯ S.D. of two independent experiments performed in triplicate. The Ct values of HepaRG at day 25 cultured in the presence of DMSO for 10 days are 23.2 for CYP4F3, 24.55 for CYP4A11, 25.08 for PPAR␣, 25.61 for PPAR␥, and 24.03 for SREBP-1c.
Days of Culture CYP4F3B CYP4A11 PPAR␣ PPAR␥ SREBP-1c
Step was detected except for a transient up-regulation of CYP4F2 and CYP4F12. It is noteworthy that induction of both P450 occurring 6 h after treatment was absent when a combination of palmitic/oleic acids was used, suggesting that a mixture of saturated FAs and MUFAs alter the cellular metabolism profile during steatosis. A previous study highlighted differences in CYP4F2 and CYP4F3 gene promoter regions and showed that saturated FAs induced CYP4F2 expression in HepG2 cells (Zhang et al., 2000) . Here, we demonstrated that CYP4F2 expression could also be up-regulated by MUFAs and PUFAs. Although CYP4F12 was proven to be approximately 10 and 50 times less efficient that CYP4A11 and CYP4F2 regarding FA hydroxylation, few data are available on its regulation. Like CYP4F2, we showed that CYP4F12 expression could be regulated by saturated or unsaturated FAs. Regarding CYP4A11 expression, it has been described that PPAR␣ contributes to its basal expression and induction during fasting in mice (Savas et al., 2009 ). However, in human, the CYP4A11 and CYP4F2 are not induced by peroxisome proliferators. In our experimental conditions, despite the fact that one cannot exclude that CYP4A11 expression might decrease after 24 h treatment, CYP4A11 and PPAR␣ expression did not seem to be correlated; whereas PPAR␣ expression decreased at 24 h, CYP4A11 expression remained stable. All saturated (data not shown) and -3, -6, and -9 FAs induced a typical microvesicular steatosis evidenced by an accumulation of . Peak 1, glucuronoconjugates; peak 2, 9,10-dihydroxystearic acid; peak 3, residual substrate; peak 4, 9,10,18-trihydroxystearic acid; peak 5, 18-hydroxy-9(10)-epoxystearic acid; peak 6, 17-hydroxy-9(10)-epoxystearic acid. lipid droplets in hepatocytes after 24-h treatment. The greatest effect was observed when HepaRG cells were treated with DHA and AA. CYP4F3B expression remained unchanged and maintained at a high level independently of the type of treatment. Meanwhile, a coordinated down-regulation of different regulator genes of lipid metabolism involved in the de novo hepatic lipogenesis was observed. Indeed, SREBP1-c, FAS, and PPAR␥ expression was down-regulated along with the expression of glycolytic and neoglucogenic enzymes leading to a limited carbon source for FA synthesis. All the effects were mainly observed after DHA treatment. Lipid accumulation in immortalized human hepatocytes was also reported to be associated with decreased lipogenesis (De Gottardi A et al., 2007) . Regarding SREBPs, -3 PUFAs were found to reduce SREBP1-c activity when fed in the diet or incubated with HepG2 hepatoma cells (Ou et al., 2001 ).
The molecular regulations of hepatic gene expression via PUFAs are complex and most probably involve several mechanisms. Previous studies showed that both PPAR␣-dependent and -independent pathways occur in the liver (Ren et al., 1997) . It is noteworthy that PPAR␣ was inhibited in HepaRG cells despite the accumulation of PUFAs, which is usually responsible for its activation (Hardwick et al., 2009) . A hepatic refractoriness to activate PPAR␣ has been well documented in metabolic syndrome-associated steatohepatitis (Larter et al., 2010) . PPAR␣ mRNA expression was also found down-regulated in hepatocytes after chylomicron remnant particle treatment. Note that chylomicron remnant particle treatment enriched in n-3 PUFAs seemed to be more potent than those rich in n-6 PUFAs (Zheng et al., 2002) . In agreement with the latter observation, we found an important inhibition of PPAR␣ after exposure to DHA reported as a major substrate for CYP4F2 and CYP4F3B and a powerful hypolipidemic compound (Kris-Etherton et al., 2002) . Mater et al. (1999) suggested that the regulation of lipogenic genes through FIG. 4 . mRNA expression of -hydroxylases in differentiated HepaRG cells exposed to different saturated and polyunsaturated fatty acids. Cells were treated for 6, 15, or 24 h with 50, 100, or 200 M of palmitic acid (C16:0), stearic acid (C18:0), oleic acid (C18:1, -9), linoleic acid (C18:2, -6), or a combination of palmitic/ oleic acids or 1% BSA (control) used as the lipid vehicle. CYP4F3B, CYP4A11, CYP4F2, and CYP4F12 mRNA expression was quantified by qPCR. Results are expressed as fold induction over vehicle-treated cells, set at 1, and represent the means Ϯ S.D. of two independent experiments in triplicate. PUFAs could involve PPAR␣-independent pathways. In our experimental setting, transient activation of CYP4F2 and CYP4F12 by saturated and unsaturated FAs in human hepatic cells might contribute to the fine tuning of hepatic lipid metabolism.
Altogether, our results showed many similarities between HepaRG hepatocytes and hepatocytes in vivo regarding CYP4F3B-mediated FA metabolism and demonstrated the value of the stepped-up hepatic differentiation to understand specific gene regulation. This cellular model opens new experimental avenues to improve our knowledge in factors mediating lipid metabolic pathways and their regulation by environmental conditions. This would also greatly help screening agonist and antagonist molecules for therapeutic, preventive, or curative purposes for liver diseases related to lipid metabolic disorders.
